Hotgen(SH:688068) 智通财经网·2026-01-16 10:32Core Viewpoint - The company, Hotgen Biotech (688068.SH), expects a net loss attributable to shareholders of the parent company for the year 2025 to be between -210 million to -230 million yuan, representing an increase in loss of 9.94% to 20.42% compared to the same period last year [1] Industry Impact - The in vitro diagnostic industry is facing significant challenges due to industry policies such as centralized procurement, leading to a short-term decline in domestic prices and reduced demand [1] - Changes in national tax policies for the industry have had a considerable impact on the company's overall gross margin and gross profit [1] Company Financials - The company has recognized asset impairment losses related to its operating assets, including reagents and equipment, in accordance with its consistent impairment accounting policy [1] - The company increased its investment in the joint venture, ShunJing Pharmaceutical, which has become a subsidiary and is included in the consolidated financial statements [1] - The accelerated development of the innovative drug pipeline at ShunJing Pharmaceutical has led to a significant increase in research and development expenses, adversely affecting the company's net profit [1] Joint Ventures and Investments - The company's joint ventures, including YaoJing Gene and ZhiYuan Biotech, have continued to increase their research and development investments in the field of biopharmaceutical innovation, resulting in expanded investment losses for the company [1]